Trials / Not Yet Recruiting
Not Yet RecruitingNCT07367529
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB6411 for Injection in Patients With Advanced Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 465 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB6411 for Injection | TQB6411 for Injection is administered every 21 days as a treatment cycle. |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2026-01-26
- Last updated
- 2026-01-26
Locations
34 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07367529. Inclusion in this directory is not an endorsement.